Wikisage, the free encyclopedia of the second generation, is digital heritage
Zimeldine: Difference between revisions
Jump to navigation
Jump to search
(→Links) |
No edit summary |
||
Line 1: | Line 1: | ||
While zilmelidine had a very favorable safety profile, within a year and a half of its introduction, rare case reports of Guillain–Barré syndrome emerged that appeared to be caused by the drug, prompting its manufacturer to withdraw it from the market | While zilmelidine had a very favorable safety profile, within a year and a half of its introduction, rare case reports of [[Guillain–Barré syndrome]] emerged that appeared to be caused by the drug, prompting its manufacturer to withdraw it from the market | ||
==Links== | ==Links== | ||
[https://karmel.miraheze.org/w/index.php?title=Zimeldina&oldid=8535 Karmel(miraheze)] | [https://karmel.miraheze.org/w/index.php?title=Zimeldina&oldid=8535 Karmel(miraheze)] | ||
{{Wikidata|Q203483}} | {{Wikidata|Q203483}} |
Latest revision as of 14:24, 21 March 2019
While zilmelidine had a very favorable safety profile, within a year and a half of its introduction, rare case reports of Guillain–Barré syndrome emerged that appeared to be caused by the drug, prompting its manufacturer to withdraw it from the market